View More Recent Stories

May 11, 2023 07:00AM Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
Mar 31, 2023 05:00PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 22, 2023 06:45AM Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
Mar 16, 2023 07:34AM Pyxis Oncology (PYXS) Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Mar 16, 2023 07:30AM Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Feb 13, 2023 08:00AM Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
Dec 23, 2022 04:45PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 1, 2022 07:39AM Pyxis Oncology (PYXS) Announces FDA Clearance of Two IND Applications
Dec 1, 2022 06:45AM Pyxis Oncology Announces FDA Clearance of Two IND Applications
Dec 6, 2021 08:00AM Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
View More Recent Stories